Good MorningThe market heaved a sigh of relief after Fed president Raphael Bostic said the committee could probably stick with quarter-point interest rate hikes. The news is contrary to a renewed belief the Fed could increase the pace to 50 bps per meeting, but investors should not be sanguine. The news does not suggest that inflation has been tamed or the Fed was anywhere near through with raising rates.
Regardless of the Fed's next move, the outlook for S&P 500 earnings continues to decline, and that is a weight the market can't bear forever. Sooner or later, the market will give up all hope for earnings growth in 2023 and the market decline will start in earnest. At best, the S&P 500 is range bound but headed toward the bottom of that range. The following week could be trying for the market with little to sustain the rebound regarding economic data or earnings reports. Featured: Forbes mag says this strategy "like finding money in the street" (Tradewins) 
|
Tech | | | After sweeping through battles in statehouses across the country, the war against ESG investing is heating up in Congress.
The Senate voted Wednesday to overturn a Labor Department rule allowing retirement plans to consider environmental, social and governance factors when making inve... Read the Full Story |
|
From Our PartnersMaking profits in the stock market depends on making your entry at the right time. The time is NOW to get into A.I. Artificial Intelligence is turning into one of the most popular trends this year, and it has only just begun.
(**By clicking the link you are subscribing to the The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here)
| | | | Go HERE to Reveal Which Stock These Are |
|
Stocks | | |
Gold has long been regarded as a timeless investment and a symbol of wealth. For centuries, it has been used as a store of value and a medium of exchange, maintaining its appeal even in modern times. As economies fluctuate and the stock market experiences highs and lows, gold remains a steadfast a... Read the Full Story |
|
Markets | | |
High-growth cloud computing firm Snowflake (NYSE: SNOW) reported earnings after the close on Wednesday, and the results were not what investors were hoping for. The stock dropped by 11% following the earnings report, which showed disappointing guidance.
Snowflake is one of the fastest-growing tec... Read the Full Story |
|
From Our PartnersAs tensions mount over Taiwan, China is engaging in a stealth war against the U.S. that could cripple our military production. China controls up to 90% of the critical elements needed to secure our national defense. But new mineral discoveries in America could end our dependence on China. One exploration company is well-positioned to advance U.S. national security interests. | | | | Click here for this rare investment opportunity |
|
Markets | | | When European Union chief Ursula von der Leyen visited Britain last week, some joked on social media: Can you please bring us some tomatoes? People in the U.K. have had to ration salad staples like tomatoes and cucumbers for the past two weeks amid a shortage of fresh vegetables. Shelves of fresh pr... Read the Full Story |
|
Markets | | | Asian stock markets were mixed Thursday after signs of enduring upward pressure on American prices added to expectations of higher interest rates for longer.
Shanghai and Seoul advanced while Tokyo and Hong Kong declined. Oil prices edged higher.
Wall Street declined We... Read the Full Story |
|
|
Stocks | | |
It’s too soon to call October 13th the low for U.S. stocks. With the Federal Reserve steadfast in its view of higher rates for longer, equity valuations may not have yet reached the basement.
The good news is that the stock market has distanced itself from its 2022 bottom. And with some Fed... Read the Full Story |
|
Markets | | |
If you own a portfolio of dividend stocks, you might wonder how to earn more income from your investments.
You can follow one simple strategy to unlock more income from your portfolio. This strategy involves limited risk and may also lead to appreciable upside returns.
Let’s cover th... Read the Full Story |
|
Markets | | | Chinese leader Xi Jinping’s agenda for this month’s meeting of the ceremonial national legislature: Revive the economy by encouraging consumers to spend more now that severe anti-virus controls have ended Read the Full Story |
|
Markets | | | German Chancellor Olaf Scholz on Thursday called on China to refrain from sending weapons to Russia and instead use its influence to press Moscow for the withdrawal of Russian troops from Ukraine.“My message to Beijing is clear: use your influence in Moscow to press for the withdrawal of Russian tro... Read the Full Story |
|
Stocks | | |
Oil tankers have been on an uptrend for the past year, with no real signs of slowing down. In one of the latest developments, Nordic American Tanker Ltd. (NYSE: NAT) on February 27, boosted its shareholder payout by 200%, from $0.05 a share to $0.15, according to MarketBeat data on dividend increa... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. | | View Today's Stock Pick |
|
